By Dr Maya Kansara

Conference Abstracts

Thavaneswaran S; Espinoza D; Lin FP; Chinchen S; Kansara M; Ballinger M; Grady J; Grimison P; Millward M; Ladwa R; Joshua AM; Desai J; Simes J; Thomas D, 2025, 'Phase II trial of Vismodegib in advanced cancers with Hedgehog pathway alterations', in ANNALS OF ONCOLOGY, ELSEVIER, GERMANY, Berlin, Vol. 36, presented at Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), GERMANY, Berlin, 17 October 2025 - 21 October 2025, http://dx.doi.org/10.1016/j.annonc.2025.08.1542

Southi N; Sim H-W; Grady J; Satgunaseelan L; Huang M; Kansara M; Yuile A; Zaman A; Lin F; Wheeler H; Hudson A; Ballinger ML; Thomas DM; Thavaneswaran S, 2025, 'Understanding the prevalence ofMTAP andCDKN2A/B deletion in gliomas by next generation sequencing', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, Vol. 27, pp. v252 - v252, http://dx.doi.org/10.1093/neuonc/noaf201.1004

Lin FPY; Grady JP; Napier CE; Callow M; Thavaneswaran S; Huang ML; Zaheed M; Kansara M; Sebastian L; Ballinger ML; Simes J; Thomas DM, 2024, 'Impact of artificial intelligence (AI) decision support on clinical trial participation: A before-after implementation study on a nationwide molecular tumor board.', in Journal of Clinical Oncology, Vol. 42, pp. 1557 - 1557, http://dx.doi.org/10.1200/JCO.2024.42.16_suppl.1557

Lin FP-Y; Grady JP; Napier CE; Callow M; Thavaneswaran S; Huang ML; Zaheed M; Kansara M; Sebastian L; Ballinger ML; Simes J; Thomas DM, 2024, 'Impact of artificial intelligence (AI) decision support on clinical trial participation: A before-after implementation study on a nationwide molecular tumor board', in Journal of Clinical Oncology, American Society of Clinical Oncology, Vol. 42, presented at 2024 ASCO Annual Meeting I, 29 May 2024 - 29 May 2024, http://dx.doi.org/10.1200/JCO.2024.42.16_suppl.1557

Napier CE; Lin F; Thavaneswaran S; Sebastian L; Grady J; Kansara M; Zaheed M; Simes J; Ballinger ML; Thomas DM, 2024, 'Pattern of access to genomically-linked therapies associated with pan-cancer biomarkers in advanced cancer patients: Insights from the Australian Molecular Screening and Therapeutics (MoST) program', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 20, pp. 136 - 136

Kansara M; Lin FP-Y; Thavaneswaran S; Napier CE; Grady JP; Ballinger ML; Simes J; Thomas DM, 2023, 'Genomic alterations associated with response to immune checkpoint inhibitors in rare cancers: A biomarker exploration study from the Australian Molecular Screening and Therapeutics (MoST) Program', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, Vol. 41, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 02 June 2023 - 06 June 2023

Thavaneswaran S; Lin FP-Y; Napier CE; Grady JP; Ballinger ML; Kansara M; Grimison PS; Pavlakis N; Wong MK; Sjoquist KM; Goldstein D; Chantrill LA; Simes J; Thomas DM, 2023, 'Genomic targetability and survival outcomes of biliary tract cancers (BTC): A retrospective cohort study of the Australian Molecular Screening and Therapeutics (MoST) program', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, Vol. 41, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 02 June 2023 - 06 June 2023

Lin FP-Y; Thavaneswaran S; Napier CE; Grady JP; Kansara M; Sebastian L; Kee D; Zaheed M; Millward M; Brown MP; Charakidis M; Craft PS; Grimison PS; Harrup RA; O'Byrne KJ; Desai J; Lee CK; Ballinger ML; Simes J; Thomas DM, 2023, 'Genomic therapy matching in rare and refractory cancers: Updated results from a retrospective cohort study in the Molecular Screening and Therapeutic (MoST) program', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, Vol. 41, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 02 June 2023 - 06 June 2023

Kee D; Lin FP-Y; Thavaneswaran S; Napier CE; Harrison ML; Beale PJ; Lynch J; Davis AJ; Ananda S; Lombard JM; Friedlander M; Kansara M; Sebastian L; Lee CK; Ballinger ML; Simes J; Thomas DM, 2023, 'Molecular tumor profiling and therapy selection in advanced gynecological cancers: A retrospective cohort analysis from the Australian Molecular Screening and Therapeutics (MoST) Program', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, Vol. 41, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 02 June 2023 - 06 June 2023

Thavaneswaran S; Mersiades A; Lin FP-Y; Espinoza D; Grady JP; Lee CK; Desai J; Brown MP; Grimison PS; O'Byrne KJ; Harrup RA; Nagrial A; Sebastian L; Chinchen S; Kansara M; Craft PS; Simes MMJ; Joshua AM; Thomas DM, 2023, 'Trastuzumab emtansine (T-DM1) in advanced cancers with HER2 mutations or amplification: Results from the Molecular Screening and Therapeutics (MoST) Program substudy.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, Vol. 41, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 02 June 2023 - 06 June 2023

Huang M; Kansara M; Qiu M; Thomas D, 2023, 'Special Session - Molecular Pathology', in HISTOPATHOLOGY, WILEY, AUSTRALIA, Brisbane, Vol. 83, pp. 34 - 34, presented at 47th Annual Scientific Meeting of the Australasian-Division of the International-Academy-of-Pathology (IAP), AUSTRALIA, Brisbane, 26 May 2023 - 28 May 2023, http://dx.doi.org/10.1111/his.14990

Huang M; Kansara M; Qiu M; Thomas D, 2023, 'NTRK transcript expression and Pan-TRK protein expression in advanced rare solid tumours', in HISTOPATHOLOGY, WILEY, Vol. 83, pp. 34 - 34

Lin FP-Y; Thavaneswaran S; Grady JP; Napier CE; Kansara M; Sebastian L; Kee D; Oakes SR; Blackburn J; Scott HS; Glover A; Fox SB; Goldstein D; Leo P; Amanuel B; Desai J; Lee CK; Ballinger ML; Simes J; Thomas DM, 2022, 'Molecular therapy selection in treatment-refractory advanced cancers: A retrospective cohort study determining the utility of TOPOGRAPH knowledge base.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 40, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 03 June 2022 - 07 June 2022

Serie D; Pickering C; Rice R; Wong M; Huang H; Kansara M; Thavaneswaran S; Ballinger ML; Sebastian L; Thomas DM; Lindpaintner K, 2022, 'Serum glycoproteomic signatures and association with survival in patients with bone and soft tissue sarcoma treated with immune-checkpoint inhibitor therapy.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 40, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 03 June 2022 - 07 June 2022

Lin FP-Y; Thavaneswaran S; Grady JP; Napier CE; Kansara M; Sebastian L; Kee D; Oakes SR; Blackburn J; Scott HS; Glover A; Fox SB; Goldstein D; Leo P; Amanuel B; Desai J; Lee CK; Ballinger ML; Simes J; Thomas DM, 2022, 'Molecular therapy selection in treatment-refractory advanced cancers: A retrospective cohort study determining the utility of TOPOGRAPH knowledge base.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 3073 - 3073, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.3073

Serie D; Pickering C; Rice R; Wong M; Huang H; Kansara M; Thavaneswaran S; Ballinger ML; Sebastian L; Thomas DM; Lindpaintner K, 2022, 'Serum glycoproteomic signatures and association with survival in patients with bone and soft tissue sarcoma treated with immune-checkpoint inhibitor therapy.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 11546 - 11546, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.11546

Thomas DM, 2022, 'Heritable defects in telomere and mitotic function selectively predispose to sarcomas', in CANCER SCIENCE, WILEY, Vol. 113, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000778583800159&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Thavaneswaran S; Sebastian L; Finlayson S; Desai J; O'Byrne K; Harrup R; Ballinger ML; Lin F; Grady JP; Kansara M; Simes J; Leland SM; Jansen VM; Cavers AC; Thomas DM, 2021, 'CRESTONE: Clinical Study of REsponse to Seribantumab in Tumours with NEuregulin-1 (NRG1) Fusions: A phase 2 study of the anti-HER3 monoclonal antibody for advanced or metastatic solid tumours (MoST CRESTONE in Australia)', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 17, pp. 206 - 206, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000717281500346&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Joshua AM; Prawira A; Thavaneswaran S; Cosman R; Lee CK; Sjoquist KM; Simes J; Thomas DM; Espinoza D; Sebastian L; Ballinger ML; Hague W; Chinchen S; Collignon E; Kansara M; Palacios T; Grady J; Barker H; Thornton K, 2020, 'A signal-seeking trial of olaparib and durvalumab in homologous repair-deficient tumors: A sub-study of the cancer molecular screening and therapeutics (MoST) program.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 38, presented at Annual Scientific Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 May 2020 - 02 June 2020

Thavaneswaran S; Ballinger ML; Grady J; Cowley M; Joshua A; Sebastian L; Collignon E; Silvestri A; Kansara M; Pinese M; Sjoquist KM; Hague W; Lee CK; Simes J; Thomas DM, 2019, 'The Cancer Molecular Screening and Therapeutics Program (MoST): Actionable mutation frequencies in a population with rare and less common cancers.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, Vol. 37, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2019 - 04 June 2019, http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.3136

Back to profile page